PIK3CA, AKT1, MAPK1, STAT3

This entry encompasses four distinct core nodes in cancer signaling pathways: PIK3CA (a lipid kinase), AKT1 (a serine/threonine kinase), MAPK1 (a serine/threonine kinase), and STAT3 (a transcription factor). Each is individually a well-established and canonical therapeutic target. However, listing them as a single combined entry is inappropriate for precise structured information, as each requires separate, detailed characterization due to their unique molecular functions, specific interacting drugs, and distinct roles within complex cellular networks. Their individual dysregulation contributes to tumorigenesis, and their targeting aims to disrupt the PI3K-AKT-mTOR, RAS-RAF-MEK-ERK, and JAK-STAT pathways, respectively.

Other names

PI3K alphaPI3K p110 alphaphosphoinositide 3-kinase alphap110αProtein kinase B alpha (PKBα)AktExtracellular signal-regulated kinase 2 (ERK2)ERK2p42MAPKSTAT-3Acute-phase response factor (APRF)

This entry represents a collection of distinct therapeutic targets; mechanisms of action vary but broadly include inhibition of lipid kinase activity (PIK3CA), serine/threonine kinase activity (AKT1, MAPK1), and transcription factor activation/DNA binding (STAT3), collectively aiming to disrupt critical cancer signaling pathways such as PI3K-AKT-mTOR, RAS-RAF-MEK-ERK, and JAK-STAT.